England’s NHS will test blood-based detection of several cancers at about 200 GP practices, according to a November 4 report by the Mirror, published on AOL. The government-backed study aims to recruit 20,000 patients over 45 with symptoms such as bloating or stomach cramps, to help doctors identify who needs further investigation sooner.
The University of Birmingham lists the project, STRIDE-RCT, as active, with funding from the National Institute for Health and Care Research. Its registered project period runs from November 1, 2026, to October 31, 2031. The research concerns tests in clinical care; it does not establish their effectiveness in routine use.
According to the Mirror, the study will assess tests from three companies for signals including tumour DNA and proteins. Participants will generally provide one or two tubes of blood alongside routine tests. Doctors will record their level of suspicion of cancer, allowing researchers to examine how the tests complement clinical judgement.
The report says the target cancers include pancreatic, liver, ovarian, bowel and prostate cancer. NHS England cancer director Peter Johnson said abdominal symptoms can resemble less serious conditions. The study will evaluate the tests before any assessment of nationwide introduction; an earlier diagnosis remains an aim, not a demonstrated result.
Separate research illustrates the uncertainty. The NHS-Galleri trial’s official September results summary reported no overall difference in combined stage 3 and 4 diagnoses between tested and control groups, missing its main goal. However, stage 4 diagnoses alone were fewer in the tested group, which also had more early-stage diagnoses.
The Galleri team said further collection and analysis of data would continue. Those findings concern a different trial and do not establish STRIDE-RCT’s outcome. For the new programme, the question is whether blood testing can help doctors direct symptomatic patients toward appropriate investigations, with wider use dependent on evaluation.
Comments